for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Roche Gets FDA Approval For Cobas EZH2 Mutation Test As Companion Diagnostic For Tazverik Developed By Epizyme

June 19 (Reuters) - Roche Holding AG:

* ROCHE RECEIVES FDA APPROVAL FOR COBAS EZH2 MUTATION TEST AS A COMPANION DIAGNOSTIC FOR PATIENTS WITH FOLLICULAR LYMPHOMA

* ROCHE - COBAS EZH2 MUTATION TEST EXPECTED TO BE COMMERCIALLY AVAILABLE IN U.S. LATER THIS YEAR

* ROCHE - U.S. FDA APPROVAL OF COBAS EZH2 MUTATION TEST AS A COMPANION DIAGNOSTIC FOR TAZVERIK DEVELOPED BY EPIZYME Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up